Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Tertiary hyperparathyroidism in kidney transplant recipients is a serious condition that can persist even after a successful transplantation. This disorder has been associated with graft dysfunction, cardiovascular complications, osteopenia, and various systemic symptoms. The most appropriate first-line therapy for managing tertiary hyperparathyroidism in kidney transplant recipients is still a topic of debate.
We conducted a retrospective, single-center observational study involving kidney transplant recipients with tertiary hyperparathyroidism from a patient pool between January 2010 and January 2025. Patients were identified using the database at the Department of Nephrology, Christian Medical College, Vellore, Tamil Nadu, India. The kidney transplant recipients were categorized based on their treatment: medical management, parathyroidectomy, or no treatment. We compared serum calcium and phosphorus levels, changes in serum creatinine levels, as well as rates of death-censored and all-cause allograft failure among the treatment groups.
An interim analysis was performed on 20 kidney transplant recipients, 8 of whom underwent parathyroidectomy. Recipients with no treatment had shorter dialysis vintage, lower parathyroid hormone levels, and a later onset of hypercalcemia. Parathyroidectomy was associated with a significant reduction in serum calcium levels compared to medical management (p < 0.01). Persistent hypercalcemia was more common in the no treatment group than in the medical management and parathyroidectomy groups (p < 0.01). Treatment with either parathyroidectomy or medical management was linked to a lower risk of both death-censored allograft failure and all-cause allograft failure.
Treatment for tertiary hyperparathyroidism is associated with improved graft survival. Parathyroidectomy was found to result in a greater reduction in serum calcium levels and decreased chances of persistent hypercalcemia.
